Atypical Parkinsonism and Frontotemporal Dementia – Clinical, Pathological and Genetic Aspects

Czech version

Authors: K. Menšíková ¹; L. Tučková ²; P. Kaňovský ¹
Authors‘ workplace: Neurologická klinika LF UP a FN Olomouc ¹; Ústav klinické a molekulární patologie, LF UP a FN Olomouc ²
Published in: Cesk Slov Neurol N 2016; 79/112(3): 275-286
Category: Review Article
doi: https://doi.org/10.14735/amcsnn2016275

Overview

Frontotemporal dementia (FTD) is a heterogeneous clinical syndrome including behavioural variant FTD (bvFTD) and primary progressive aphasia (PPA), which are clinically characterized by behavioural changes and impairment of executive functions and speech. Behavioural changes and speech disorders are often accompanied by motor symptomatology, including especially parkinsonism and/or symptoms of the upper and lower motor neuron involvement. These symptoms may be present in various combinations, thereby creating a very wide spectrum of clinical entities, some of which are precisely genetically and pathologically defined. Besides these few defined entities, there is a number of variable clinical phenotypes consisting of different combinations of behavioural and personality changes, speech disorders and symptoms of typical and atypical parkinsonism associated with different mutations and histopathologic findings. These phenotypes cannot be clearly classified according to their clinical picture and instead, they are placed somewhere within the dementia-parkinsonism continuum. In our paper, we present an overview of the current state of knowledge of possible clinical manifestations of parkinsonism and FTD and their genetic and pathological aspects.

Key words:
frontotemporal dementia – primary progressive aphasia – progressive supranuclear palsy – corticobasal syndrome – frontotemporal lobar degenerations

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Sources

1. Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006;66(1):41–8.

2. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76(11):1006– 14. doi: 10.1212/WNL.0b013e31821103e6.

3. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134(9):2456– 77. doi: 10.1093/brain/awr179.

4. Snowden JS, Neary D, Mann DM. Frontotemporal dementia. Br J Psychiatry 2002;180:140– 3.

5. Ratnavalli E, Brayne C, Dawson K, et al. The prevalence of frontotemporal dementia. Neurology 2002;58(11):1615– 21.

6. Harvey RJ, Skelton-Robinson M, Rossor M. The prevalence and causes of dementia in People under the age of 65 years. J Neuro Neurosurg Psychiatry 2003;74(9):1206– 9.

7. Borroni B, Alberici A, Grassi M, et al. Is frontotemporal lobar degeneratin a rare disorder? Evidence from a preliminary study in Brescia County, Italy. J Alzhemiers Dis 2010;19(1):111– 6. doi: 10.3233/JAD-2010-1208.

8. Seelaar H, Kamphorst W, Rosso SM, et al. Distinct genetic forms of frontotemporal dementia. Neurology 2008;71(16):1220– 6. doi: 10.1212/01.wnl.0000319702.37497.72.

9. Hodges JR, Davies R, Xuereb J, et al. Survival in frontotemporal dementia. Neurology 2003;61(3):349– 54.

10. Pick A. Über die Bezeihungen der senilen Hirnatrophie zur Aphasie. Prager Medicinische Wochenschrift 1892;17:165– 7.

11. Alzheimer A. Über eigenartige Krankheitsfälle des späteren Alters. Z Ges Neurol Psychiatr 1911:1914.

12. Onari K, Spatz H. Anatomische Beträge zur Lehre von der Pickschen umschribenen Groβhirnrinden-Atrophie („Picksche Kranheit“). Z Ges Neurol Psychiatr 1926;101:470– 511.

13. Pollock NJ, Mirra SS, Binder LI, et al. Filamentous aggregates in Pick’s disease, progressive supranuclear palsy and Alzheimer’s disease share antigenic determinants with mikrotubule-associated protein Tau. Lancet 1986;328:1211.

14. Brun A, Englund B, Gustafson L. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatr 1994;57(4):416– 8.

15. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010;119(1):1–4. doi: 10.1007/s00401-009-0612-2.

16. Goedert M, Spillantini MG, Jakes R, et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer‘s disease. Neuron 1989;3(4):519– 26.

17. van Swieten J, Spillantini MG. Hereditary frontotemporal dementia caused by tau gene utations. Brain Pathol 2007;17(1):63–73.

18. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314(5796):130– 3.

19. Mackenzie IR, Neumann M, Cairns NJ, et al. Novel types of frontotemporal lobar degeneration: beyond Tau and TDP-43. J Mol Neurosci 2011;45(3):402– 8. doi: 10.1007/s12031-011-9551-1.

20. Munoz DG, Neumann M, Kusaka H, et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol 2009;118(5):617– 27. doi: 10.1007/s00401-009-0598-9.

21. Neumann M, Rademakers R, Roeber S, et al. A new subtype of frontotemporal lobardegeneration with FUS pathology. Brain 2009;132(11):2922– 31. doi: 10.1093/ brain/awp214.

22. Urwin H, Josephs KA, Rohrer JD, et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol 2010;120(1):33– 41. doi: 10.1007/s00401-010-0698-6.

23. Neumann M, Roeber S, Kretzschmar HA, et al. Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 2009;118(5):605– 16. doi: 10.1007/s00401-009-0581-5.

24. Munoz-Garcia D, Ludwin SK. Classic and generalized variants of Pick’s disease: a clinicopathological, ultrastructural, and immunocytochemical comparative study. Ann Neurol 1984;16(4):467– 80.

25. Yokota O, Tsuchiya K, Terada S, et al. Basophilic inclusion body disease and neuronal intermediate filament inclusion disease: a comparative clinicopathological study. Acta Neuropathol 2008;115(5):561– 75.

26. Kusaka H, Matsumoto S, Imai T. An adult-onset case of sporadic motor neuron disease with basophilic inclusions. Acta Neuropathol 1990;80(6):660– 5.

27. Kusaka H, Matsumoto S, Imai T. Adult-onset motor neuron disease with basophilic intraneuronal inclusion bodies. Clin Neuopathol 1993;12(4):215– 8.

28. Tsuchiya K, Matsunaga T, Aoki M, et al. Familial amyotrophic lateral sclerosis with posterior column degeneration and basophilic inclusion bodies: a clinical, genetic and pathological study. Clin Neuropathol 2001;20(2):53– 9.

29. Hamada K, Fukazawa T, Yanagihara T, et al. Dementia with ALS features and diffuse Pick body-like inclusions (atypical Pick’s disease?). Clin Neuropathol 1995;14(1):1– 6.

30. Ishihara K, Araki S, Ihori N, et al. An autopsy case of frontotemporal dementia with severe dysarthria and motor neuron disease showing numerous basophilic inclusions. Neuropathology 2006;26(5):447– 54.

31. Cairns NJ, Grossman M, Arnols SE, et al. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 2004;63(8):1376–84.

32. Mackenzie IR, Munoz DG, Kusaka H, et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol 2011;121(2):207– 18. doi: 10.1007/s00401-010-0764-0.

33. Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005;37(8):806–8.

34. van der Zee J, Urwin H, Engelborghs S, et al. CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum Mol Genet 2008;17(2):313–22.

35. Rohrer JD, Guerreiro R, Vandrovcova J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 2009;73(18):1451– 6. doi: 10.1212/WNL.0b013e3181bf997a.

36. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72(2):245– 56. doi: 10.1016/j.neuron.2011.09.011.

37. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72(2):257– 68. doi: 10.1016/j.neuron.2011.09.010.

38. Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 2010;74(2):97– 109. doi: 10.1111/j.1469-1809.2009.00560.x.

39. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 59-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393(6686):702–5.

40. Goedert M, Spillantini MG, Potier MC, et al. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989;8(2):393–9.

41. van Swieten JC, Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol 2008;7(10):965–74. doi: 10.1016/S1474-4422(08)70194-7.

42. Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 2006;15(20):2988–3001.

43. Le Ber I, Camuzat A, Hannequin D, et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain 2008;131(3):732–46. doi: 10.1093/brain/awn012.

44. Beck J, Rohrer JD, Campbell T, et al. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain 2008;131(3):706–20. doi: 10.1093/brain/awm320.

45. Kelley BJ, Haidar W, Boeve BF, et al. Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging 2009;30(5):739–51.

46. Bigio EH. C9ORF72, the new gene on the block, causes C9FTD/ ALS: new insights provided by neuropathology. Acta Neuropathol 2011;122(6):653–5. doi: 10.1007/s00401-011-0919-7.

47. van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C-ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 2013;12(10):978– 88. doi: 10.1016/S1474-4422(13)70210-2.

48. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012;11(4):323–30. doi: 10.1016/S1474-4422(12)70043-1.

49. Herdewyn S, Zhao H, Moisse M, et al. Whole-genome sequencing reveals a coding non-pathogenic variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of amyotrophic lateral sclerosis. Hum Mol Genet 2012;21(11):2412–9. doi: 10.1093/hmg/ dds055.

50. Mori K, Weng SM, Arzberger T, et al. The C9or72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ ALS. Science 2013;339(6125):1335–8. doi: 10.1126/science.1232927.

51. Kimonis VE, Fulchiero E, Vesa J, et al. VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim Biophys Acta 2008;1782(12):744– 8. doi: 10.1016/j.bbadis.2008.09.003.

52. Benajiba L, Le Ber I, Camuzat A, et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol 2009;65(4):470– 3. doi: 10.1002/ana.21612.

53. Kwiatkowski TJ, Bosco DA, Leclerc AL, et al. Mutations in the FUS/ TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323(5918):1205– 8. doi: 10.1126/science.1166066.

54. Van Langenhove T, van der Zee J, Sleegers K, et al. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology 2010;74(5):366-71. doi: 10.1212/WNL.0b013e3181ccc732.

55. Seelaar H, Kamphorst W, Rosso SM, et al. Distinct genetic forms of frontotemporal dementia. Neurology 2008;71:1220– 6. doi: 10.1212/01.wnl.0000319702.37497.72.

56. Kfoury N, Holmes BB, Jiang H, et al. Transcellular propagation of tau aggregation by fibrillar species. J Biol Chem 2012;287(23):19440– 51. doi: 10.1074/jbc.M112.346072.

57. Guo CC, Gorno-Tempini ML, Gesierich B, et al. Anterior temporal lobe degeneration produces widespread network-driven dysfunction. Brain 2013;136(10):2979– 91. doi: 10.1093/brain/awt222.

58. Rosen HJ, Gorno-Tempini ML, Goldman WP, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002;58(2):198–208.

59. Liu W, Miller BL, Kramer JH, et al. Behavioral disorders in the frontal and temporal variants of frontotemporal dementia. Neurology 2004;62(5):742–8.

60. Marczinski CA, Davidson W, Kertesz A. A longitudinal study of behavior in frontotemporal dementia and primary progressive aphasia. Cogn Behav Neurol 2004;17(4): 185–90.

61. Kramer JH, Jurik J, Sha SJ, et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol 2003;16(4):211–8.

62. Kipps CM, Hodges JR, Hornberger M. Nonprogressive behavioural frontotemporal dementia: recent developments and clinical implications of the ’bvFTD phenocopy syndrome’. Curr Opin Neurol 2010;23(6):628– 32. doi: 10.1097/WCO.0b013e3283404309.

63. Khan BK, Yokoyama JS, Takada LT, et al. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry 2012;83(4):358– 64. doi: 10.1136/jnnp-2011-301883.

64. Grossman M. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol 2010;6(2):88–97. doi: 10.1038/nrneurol.2009.216.

65. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76(111):1006–14. doi: 10.1212/WNL.0b013e31821103e6.

66. Snowden JS, Thompson JC, Stopford C, et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 2011;134(9):2478–92. doi: 10.1093/brain/awr189.

67. Mesulam MM. Primary progressive aphasia. Ann Neurol 2001;49(4):425–32.

68. Catani M, Mesulam MM, Jakobsen E, et al. A novel frontal pathway underlies verbal fluency in primary progressive aphasia. Brain 2013;136(8):2619– 28. doi: 10.1093/brain/awt163.

69. Ash S, Evans E, O’Shea J, et al. Differentiating primary progressive aphasias in a brief sample of connected speech. Neurology 2013;81(4):329– 36. doi: 10.1212/WNL.0b013e31829c5d0e.

70. Thompson SA, Patterson K, Hodges JR. Left/ right asymmetry of atrophy in semantic dementia: behavioral-cognitive implications. Neurology 2003;61(9):1196–203.

71. Ioannidis P, Konstantinopoulou E, Maiovis P, et al. The frontotemporal dementias in a tertiary referral center: classification and demographic characteristics in a series of 232 cases. J Neurol Sci 2012;318(1–2):171– 3. doi: 10.1016/j.jns.2012.04.002.

72. Espay AJ, Litvan I. Parkinsonism and frontotemporal dementia: the clinical overlap. J Mol Neurosci 2011;45(3):343– 9. doi: 10.1007/s12031-011-9632-1.

73. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 2009;117(1):15– 8. doi: 10.1007/s00401-008-0460-5.

74. Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007;114(1):5–22.

75. Kovacs GG, Majtenyi K, Spina S, et al. White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol 2008;67(10):963–75. doi: 10.1097/NEN.0b013e318187a80f.

76. Josephs KA, Knopman DS, Whitwell JL, et al. Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs FTLD-MND. Neurology 2005;65(4):645–7.

77. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442(7105):916–9.

78. Farrer MJ, Hulihan MM, Kachergus JM, et al. DCTN1 mutations in Perry syndrome. Nat Genet 2009;41(2):163– 5. doi: 10.1038/ng.293.

79. Aji BM, Medley G, O‘Driscoll K, et al. Perry syndrome: a disorder to consider in the differential diagnosis of Parkinsonism. J Neurol Sci 2013;330(1– 2):117– 8. doi: 10.1016/j.jns.2013.04.008.

80. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004;36(4):377–81.

81. Rutherford NJ, Zhang YJ, Baker M, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet 2008;4(9):e1000193. doi: 10.1371/journal.pgen.1000193.

82. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013;2: 609–22.

83. Ludolph AC, Kassubek J, Landwehrmeyea BG, et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol 2009;16(3):297– 309. doi: 10.1111/j.1468-1331.2008.02513.x.

84. Carney RM, Kohli MA, Kunkle BW, et al. Parkinsonism and distinct dementia patterns in a family with the MAPT R406W mutation. Alzheimers Dement 2014;10(3):360– 5. doi: 10.1016/j.jalz.2013.02.011.

85. Baba Y, Tsuboi Y, Baker MC, et al. The effect of tau genotype on clinical features in FTDP-17. Parkinsonism Relat Disord 2005;11(4):205–8.

86. Puschmann A. Monogenic Parkinson‘s disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord 2013;19(4):407–15. doi: 10.1016/j.parkreldis.2013.01.020.

87. Boeve BF, Hutton M. Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch Neurol 2008;65(4):460–4. doi: 10.1001/archneur.65.4.460.

88. Rademakers R, Cruts M, van Broeckhoven C. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 2004;24(4):277–95.

89. Fujioka S, Wszolek ZK. Clinical aspects of familial forms of frontotemporal dementia associated with parkinsonism. J Mol Neurosci 2011;45(3):359– 65. doi: 10.1007/s12031-011-9568-5.

90. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442(7105):920–4.

91. Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 2006;15(20):2988–3001.

92. Le Ber I, Camuza A, Hannequin D, et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain 2008;131(3):732– 46. doi: 10.1093/ brain/awn012.

93. Benussi L, Ghidoni R, Pegoiani E, et al. Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. Neurobiol Dis 2009;33(3):379– 85. doi: 10.1016/j.nbd.2008.11.008.

94. Moreno F, Indakoetxea B, Barandiaran M, et al. “Frontotemporoparietal” dementia: clinical phenotype associated with the c.709-1G>A PGRN mutation. Neurology 2009;73(17): 1367– 74. doi: 10.1212/WNL.0b013e3181bd82a7.

95. Schofield EC, Halliday GM, Kwok J, et al. Low serum progranulin predicts the presence of mutations: a prospective study. J Alzheimers Dis 2010;22(3):981-4.

96. Kelley BJ, Haidar W, Boeve BF, et al. Prominent phenotypic variability associated with mutations in progranulin. Neurobiol Aging 2009;30(5):739– 51.

97. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003;54(Suppl 5):S15– 9.

98. van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 2013;12(10):978– 88. doi: 10.1016/S1474-4422(13)70210-2.

99. Boeve BF, Boylan KB, Graff-Radford NR, et al. Characterization of frontotemporal dementia and/ or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 2012;135(3):765– 83. doi: 10.1093/brain/aws004.

100. Smith BN, Newhouse S, Shatunov A, et al. The C9ORF72 expansion mutation is a common cause of ALSţ/ -FTD in Europe and has a single founder. Eur J Hum Genet 2013;21(1):102– 8. doi: 10.1038/ejhg.2012.98.

101. Waldo ML, Gustafson L, Nilsson K, et al. Frontotemporal dementia with a C9ORF72 expansion in a Swedish family: clinical and neuropathological characteristics. Am J Neurodegener Dis 2013;2(4):276– 86.

102. Friedland RP, Shah JJ, Farrer LA, et al. Behavioral variant frontotemporal lobar degeneration with amyotrophic lateral sclerosis with a chromosome 9p21 hexanucleotide repeat. Front Neurol 2012;3:136. doi: 10.3389/fneur.2012.00136.

103. Savica R, Adeli A, Vemuri P, et al. Characterization of a family with c9FTD/ ALS associated with the GGGGCC repeat expansion in C9ORF72. Arch Neurol 2012;69(9):1164– 9. doi: 10.1001/archneurol.2012.772.

104. Yeh TH, Lai SC, Weng YH, et al. Screening for C9orf72 repeat expansions in parkinsonian syndromes. Neurobiol Aging 2013;34(4):1311.e3– 4. doi: 10.1016/j.neurobiolaging.2012.09.002.

105. Lindquist SG, Duno M, Batbayli M, et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin Genet 2013;83(3):279– 83. doi: 10.1111/j.1399-0004.2012.01903.x.

106. Arvanitakis Z. Update on frontotemporal dementia. Neurologist 2010;16(1):16– 22. doi: 10.1097/NRL.0b013e3181b1d5c6.

107. Gydesen S, Brown JM, Brun A, et al. Chromosome 3linked frontotemporal dementia (FTD-3). Neurology 2002;59(10):1585– 94.

108. Stokholm J, Teasdale TW, Johannsen P, et al. Cognitive impairment in the preclinical stage of dementia in FTD-3 CHMP2B mutation carriers: a longitudinal prospective study. J Neurol Neurosurg Psychiatry 2013;84(2):170– 6. doi: 10.1136/jnnp-2012-303813.

109. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin--containing protein. Nat Genet 2004;36(4):377– 81.

110. Spina S, Van Laar AD, Murrell JR, et al. Phenotypic variability in three families with valosin-containing protein mutation. Eur J Neurol 2013;20(2):251– 8. doi: 10.1111/j.1468-1331.2012.03831.x.

111. van der Zee J, Pirici D, Van Langenhove T, et al. Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. Neurology 2009;73(8):626– 32. doi: 10.1212/WNL.0b013e3181b389d9.

112. Mehta SG, Khare M, Ramani R, et al. Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and/ or frontotemporal dementia. Clin Genet 2013;83(5):422– 31. doi: 10.1111/cge.12000.

113. Chan N, Le C, Shieh P, et al. Valosin-containing protein mutation and Parkinson‘s disease. Parkinsonism Relat Disord 2012;18(1):107– 9. doi: 10.1016/j.parkreldis.2011.07.006.

114. Rayaprolu S, Fujioka S, Traynor S, et al. TARDBP mutations in Parkinson‘s disease. Parkinsonism Relat Disord 2013;19(3):312– 5. doi: 10.1016/j.parkreldis.2012.11.003.

115. Mosca L, Lunetta C, Tarlarini C, et al. Wide phenotypic spectrum of the TARDBP gene: homozygosity of A382T mutation in a patient presenting with amyotrophic lateral sclerosis, Parkinson‘s disease, and frontotemporal lobar degeneration, and in neurologically healthy subject. Neurobiol Aging 2012;33(8):1846.e1– 4. doi: 10.1016/j.neurobiolaging.2012.01.108.

116. Kwiatkowski TJ, Bosco DA, LeClerc AL, et al. Mutations in the FUS/ TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323(5918):1205– 8. doi: 10.1126/science.1166066.

117. Gao K, Zheng W, Deng X, et al. Genetic analysis of the fused in sarcoma gene in Chinese Han patients with Parkinson‘s disease. Parkinsonism Relat Disord 2014;20(1):119– 21. doi: 10.1016/j.parkreldis.2013.09.010.

118. Labbe C, Rayaprolu S, Soto-Ortolaza A, et al. Investigating FUS variation in Parkinson‘s disease. Parkinsonism Relat Disord 2014;20(Suppl 1):S147– 9. doi: 10.1016/S1353-8020(13)70035-X.

119. Van Langenhove T, van der Zee J, Van Broeckhoven C. The molecular basis of the frontotemporal lobar degeneration - amyotrophic lateral sclerosis spectrum. Ann Med 2012;44(8):817– 28. doi: 10.3109/07853890.2012.665471.

120. Boroni B, Benussi A, Archetti S, et al. CSF p-tau181/ tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph Lateral Scler Frontotemporal Degener 2015;16(1– 2):86– 91. doi: 10.3109/21678421.2014.971812.

121. Mackenzie IR, Neumann M, Baborie A et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011;122(1):111–3. doi: 10.1007/s00401-011-0845-8.